US industry pushes to speed up Mutual Recognition Agreement (MRA) negotiations
This article was originally published in Clinica
US medical device industry executives recently offered a proposal for speeding up negotiations on the US-EU mutual recognition agreement for medical technology. At an April 24th meeting with Deputy US Trade Representative Jeff Lang, the executives said that the FDA might be able to satisfy EU demands for a larger list of products that could be made subject to a third-party pilot programme under the MRA if the agency makes some adjustment in the way it is drafting guidance documents.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.